Goodwin advised longtime client Moderna Therapeutics in its recent $500 million equity financing round which includes support from new U.S. and international institutional investors, and existing institutional investors. New investors include a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), BB Biotech AG, Julius Baer, Singapore-based EDBI and Sequoia Capital China. Existing investors that also participated in this round include Fidelity Management & Research Company, Pictet, Viking Global Investors, ArrowMark Partners and Alexandria Venture Investments.
The firm also represented Moderna in the closing of its $474 million financing round in September 2016.
For additional details on the financing round, please read the press release.